(Total Views: 1034)
Posted On: 07/06/2020 10:38:01 PM
Post# of 154141
“The saving grace is we will have data proving superiority.”
Exactly. The severe trial will fully enroll and we will know how well leronlimab works. If the results are clear, and superior to any other drug currently approved for COVID19, leronlimab will be approved.
CYDY investors should not forget that there are typically multiple drugs that are approved for one indication. This is true for general pain, headaches, diarrhea, GERD, and the list goes on. The same will happen with COVID.
Additionally, COVId doesn’t Appear to be going anywhere. So even if the interim analysis of the severe trial doesn’t result in approval, and the trial doesn’t finish until Sep/Oct, the opportunity for approval will still be there.
Exactly. The severe trial will fully enroll and we will know how well leronlimab works. If the results are clear, and superior to any other drug currently approved for COVID19, leronlimab will be approved.
CYDY investors should not forget that there are typically multiple drugs that are approved for one indication. This is true for general pain, headaches, diarrhea, GERD, and the list goes on. The same will happen with COVID.
Additionally, COVId doesn’t Appear to be going anywhere. So even if the interim analysis of the severe trial doesn’t result in approval, and the trial doesn’t finish until Sep/Oct, the opportunity for approval will still be there.
(8)
(0)
